BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2024 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2023. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Internal Procedures and Conduct for Regulating, Monitoring, and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons of the Company and their immediate relatives of the Company from January 01, 2024, and shall remain closed until 48 hours after the announcement of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2023.